The Transformative Collaborative Project Award (TCPA) provides research support for a limited time (up to 24 months) to enable eligible investigators to acquire key pieces of knowledge and/or to develop new technologies and tools that will help the consortium reach its ultimate goal of providing cell-based therapeutic solutions to the chronic depletion of beta cell mass observed in type-1 and severe type-2 diabetes. The TCPA program supports established investigators exploring innovative new directions in the fields of beta cell development, stem cells, tissue engineering, in vivo imaging, animal models of engraftment, pancreatic beta cell regeneration and physiology, and immunology and autoimmunity. The goal of the BCBC is to accelerate development of efficient cell-based therapies for insulin delivery, and/or identify innovative therapeutic strategies to enhance the regenerative capacity of the human adult endocrine pancreas.
2011-2012 TCPA Collaboration Network
Project team leaders are flagged with a yellow star, .
Rational maturation of beta cells based on in-depth profiling
Establishing immunological tolerance to transplanted pancreatic beta-cells
Investigation of New Permissive Environments for Beta Cell Engraftment
3-D growth of pancreatic beta cells from human pluripotent stem cells
THERAGNOSTIC NANOPARTICLES FOR THERAPY AND IMAGING IN TYPE 1 DIABETES
Enhancer-based beta-cell programming strategies
Non-neoplastic replication to expand functional beta-cell mass
Proteomic analysis of mesenchymal factors